All In Biotech

Drug Trial Radar · NCT02658344

Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis

Multicenter, Randomized, Double-Blind, Placebo Controlled Phase Ⅱb Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis

Last checked: Nov 19, 2026Latest source record: Jun 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jul 2015

Primary completion

Nov 2016

Study completion Dec 2016

Sponsor

Lead sponsor
R-BioIndustry
Sponsor type
Industry
First posted
Jan 18, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with Knee Osteoarthritis.

Conditions

  • Degenerative Arthritis
  • Knee Osteoarthritis

Interventions

  • JOINTSTEMBiological

    Jointstem (Autologous Adipose Tissue derived MSCs 1x10\^8cells/3ml), 1 time injection

  • Saline solutionDrug

    Saline solution (Sodium chloride 9mg/ml), 1 time injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. WOMAC scoreTime frame: 24 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • KyungHee University Gangdong Hospital

    Seoul, South Korea

  • GangNam Severance Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.